ABIOMED Issues Update on AbioCor Heart Program Status; Clinical Trial To Begin Soon
ABIOMED, Inc. (NASDAQ:ABMD) announced today that while device and team readiness have been demonstrated for several weeks, the first human implantation of […]
US Medicare Boosts Abiomed Heart Device Payment
CHICAGO (Reuters) – Abiomed Inc., developer of the first self-contained artificial heart, on Thursday said that the U.S. Medicare program boosted the […]
Abiomed Says FDA OKs AbioCor Heart Patient Group
CHICAGO (Reuters) – Medical device maker Abiomed Inc. said on Monday that U.S. regulators have taken preliminary steps toward approval of its […]
Abiomed May Not Meet Enrollment Timeline in Mechanical Heart Trial
Abiomed Inc. said on Wednesday that it is slowing patient enrollment in a clinical trial of its AbioCor implantable self-contained mechanical heart […]
Abiomed to Test Smaller Artificial Heart in 2004
The maker of the self-contained artificial heart that has so far been implanted in five patients said on Wednesday it expects to […]
ABIOMED Gets O.K. from FDA to Begin Human Implants of Artificial Heart
ABIOMED, Inc. (NASDAQ:ABMD), a leader in heart assist and replacement technology, announced today that it has received permission from the Food and […]
Abiomed Permitted to Implant Artificial Hearts in Five More Patients
Abiomed Inc. said on Monday that it has received permission from the US Food and Drug Administration (FDA) to implant its mechanical […]
ABIOMED Announces First European Site for AbioCor Implantable Replacement Heart Clinical Trial
ABIOMED, Inc. (NASDAQ:ABMD) today announced that the North Rhine-Westphalia Heart Center, Bad Oeynhausen, Germany will serve as a European clinical trial site […]
Improvement Maintained for 2 Years After Cardiac Transplant in AIDS Patient
NEW YORK (Reuters Health) – A patient with advanced but controlled HIV infection continues to do well more than 2 years after […]
Albumin Volume Expansion Lowers Mortality After Bypass Surgery
NEW YORK (Reuters Health) – Volume expansion with albumin brings lower mortality rates than does nonprotein colloid volume expansion after coronary artery […]
Volume Expansion With Albumin Decreases Mortality After Coronary Artery Bypass Graft Surgery
OBJECTIVES: Albumin and nonprotein colloids (starches, dextran, and others) are used frequently as blood volume expanders in coronary artery bypass graft (CABG) […]